[Individualization of drug therapy and pharmacogenetics].

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

[Individualization of drug therapy and pharmacogenetics].

Nihon rinsho. Japanese journal of clinical medicine - 1 Mar 1998

Yamamoto I, Azuma J

Abstract excerpt

This brief review discusses the relationship between genetic polymorphism of drug metabolizing enzyme and drug's safety and efficacy. When elimination occurs via a single metabolic pathway, individual differences in metabolic rates can lead to large differences in drug and metabolite concentratio...

Topics

Anticoagulants
Aryl Hydrocarbon Hydroxylases
Arylamine N-Acetyltransferase
Azathioprine
Cytochrome P-450 CYP2C19
Cytochrome P-450 CYP2C9
Cytochrome P-450 CYP2D6
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Enzyme System
Genetic Variation
Humans
Immunosuppressive Agents
Methyltransferases
Mixed Function Oxygenases
Mutation
Omeprazole
Polymorphism, Genetic
Steroid 16-alpha-Hydroxylase

Source

Open in PubMed

Identifiers

PMID: 9549339

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-9549339-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics